NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (Nasdaq:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that the Company will host a panel discussion titled, “New Treatment Prospects for AATD Patients: Results from a Phase 2/3 Inhaled AAT Trial,” which will be led by Key Opinion Leaders (KOLs) who specialize in treating patients with alpha-1 antitrypsin deficiency (AATD) during the upcoming American Thoracic Society (ATS) 2015 International Conference being held May 15-20, 2015 in Denver, Colorado.
Help employers find you! Check out all the jobs and post your resume.
